Class ITerminatedD-063-2013
Drug recall · December 5, 2012
Reumofan Plus Tablets recall
Why: Marketed without an approved NDA/ANDA: Samantha Lynn Inc. is recalling Reumofan Plus Tablets because it contains undeclared drug ingredients making it an unapproved drug.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Reumofan Plus Tablets, 30-count bottle per Box, (remaining label information in Spanish)
- Lots / codes
all lots within expiry through 2016
- Quantity
- 25,888 Boxes
- Company
- Samantha Lynn, Inc, Norwalk, CA
- Distribution
- Nationwide and Canada, Australia, Germany, Brazil, Austria, United Kingdom, India, Chile, Switzerland, Thailand, Japan
- Initiated
- August 27, 2012 · Voluntary: Firm initiated
- Classified
- November 23, 2012
- Reported
- December 5, 2012
- Ended
- March 18, 2013
- How notified
- Press Release
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.